

癌別：卵巢癌		
Adjuvant	最近改版日期	115.02
	處方內容	(1) Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs), or Carboplatin (AUC 6) (N/S 500 c.c.; ≥ 4hrs) q 4 wks + Paclitaxel 135 mg/m² (N/S 500 c.c.; 3 hrs) q 4wks or 85 mg/m² (N/S 300 c.c.; 2hrs) q 2wks VI (NEJM 1996;334 (1):1-6) (2) (A) ↔ (B) q 2wks VI (A) Cisplatin 60 mg /m² (N/S 500 c.c.; ≥ 4hrs) +MMC 8 mg /m² (N/S 100 c.c.; 30 mins) (Am J Clin Oncol 2004 Oct; 27(5):461-4) (B) Epirubicin 50 mg/m² (N/S 100 c.c.; 30 mins)+ Endoxan 600 mg/m² (N/S 300 c.c.; 2hrs) (Cancer, 1980;46:669-74) (Proc AMSCO 1986; 5:123 (R.R.:50-60%)) (3) Docetaxel (自 費) 60,75 mg/ m² (N/S 100 c.c.; 1hr) q 4wks or 35,40 mg/m² (N/S 100 c.c.; 1hr) q 2 wks (JCO 1999 Jul; 17(7):2069-80)

癌別：卵巢癌		
	最近改版日期	115.02
	Palliative 處方內容	(1)Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs), or Carboplatin (AUC 6) (N/S 500 c.c.; ≥ 4hrs), q 4 wks, combined with (A) or (B) (A)Paclitaxel 135 mg/m² (N/S 500 c.c.; 3 hrs) q 4wks or 85 mg/m² (N/S 300 c.c.; 2hrs)q 2wks (NEJM 1996;334 (1):1-6) (B)Docetaxel (自費)60,75 mg/ m² (N/S 100 c.c.; 1hr) q 4wks or 35,40 mg/m² (N/S 100 c.c.; 1hr) q 2wks (JCO 1999 Jul; 17(7):2069-80) (Oncology,Jun 1,2002) (2)(A) ↔ (B) q 2wks (A) Cisplatin 60 mg /m² (N/S 500 c.c.; ≥ 4hrs) +MMC 8 mg /m² (N/S 100 c.c.; 30 mins) (Am J Clin Oncol 2004 Oct; 27(5):461-4) (B) Epirubicin 50 mg/m² (N/S 100 c.c.; 30 mins)+ Endoxan 600 mg/m² (N/S 300 c.c.; 2hrs) (Cancer, 1980;46:669-74) (Proc AMSCO 1986; 5:123 (R.R.:50-60%)) (3)Lipo-dox 35 mg/m² (or 45 mg/m² for used alone) (D5W 300 c.c.; 90 mins) q 4wks or 20 mg/m² (D5W 300 c.c.; 90 mins) q 2wks (91/3/1 健保條例 9.14 : for failure to Platinum & Paclitaxel) (Gynecologic Oncology Vol.112 Issue 1 Jan. 2009; pp35-39) (4)Gemcitabine 1000 mg/ m² (N/S 100 c.c.; 30 mins) q 2wks (96/5/1、99/10/1 健保條例 9.4 : > 6 months after Platinum) (Int J Gynecol Cancer 2005 May-Jun; 15 Suppl 1:36-41) (5)Docetaxel (自費) 60,75 mg/ m² (N/S 100 c.c.; 1hr) q 4wks or 35,40 mg/m² (N/S 100 c.c.; 1hr) q 2 wks (JCO 1999 Jul; 17(7):2069-80) (6)Topotecan 1 or 1.2 mg/ m²/d (N/S 100 c.c.; 30 mins) * 3-5days q28d(JCO 1997; 15:2183-93) (88/10/1、93/8/1 健保條例 9.16.1:2 nd line; failure to Platinum) (7)Pemetrexed 500 mg/ m² (N/S 100 c.c.; 20 mins) 4wks (JCO 2008; 35:5761-5766) (8)Oral Etoposide (50 mg) 2[#]-3[#] /wk (Drugs 1999;58 Suppl 3:43-9) (9)Consider Bevacizumab 5mg/kg (N/S 100 c.c. ; 20 mins) (109/6/1 健保條例 9.37:2nd line, failure to Platinum) (10)Olaparib (600 mg)/day (109/11/1 健保條例 9.85:單獨使用 或合併 Bevacizumab as

		Maintenance therapy) (11)Niraparib(300 mg)/day(113/3/1 健保條例 9.85)
--	--	--